Drug development and chemotherapy in acute lymphoblastic leukemia: Of mice to men

Cancer

Volumn 83, Issue 9, 1998, Pages 1885-1888

  Reaman, Gregory H ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; CARBAMIC ACID DERIVATIVE; CHLORMETHINE DERIVATIVE; COLCHICINE; GLUCOCORTICOID; PREDNISONE; URETHAN; VASOPRESSIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BRAIN LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CHILDHOOD CANCER; CLINICAL TRIAL; DISEASE MODEL; DRUG DEVELOPMENT; DRUG SCREENING; DRUG TARGETING; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT;

ANIMALS; CHILD; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MICE; RANDOMIZED CONTROLLED TRIALS;

EID: 0032212490     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981101)83:9<1885::AID-CNCR1>3.0.CO;2-Z     Document Type: Review

References (31)

1. Burchenal JH. The newer nitrogen mustards in the treatment of leukemia. Radiology 1948;50:494-9.
2. Karnofsky DA, Craver LF, Rhoads CP, Abels JC. An evaluation of methy-bis (β-chlorethyl) amine hydrochloride and tris (β-chloroethyl) amine hydrochloride (nitrogen mustards) in the treatment of lymphomas, leukemia and allied diseases. In [AAAS] Approaches to tumor chemotherapy. 1947:319-37.
3. Flory CM, Furth J, Saxton JA Jr., Reiner L. Chemotherapeutic studies on transmitted mouse leukemia. Cancer Res 1943;3: 729-43.
4. Furth J, Ferris HW, Reznikoff P. Relation of leukemia of animals to leukemia of man. JAMA 1935;105:1824-183c.
5. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-Aminopteroyl-glutamic acid (Aminopterin). N Engl J Med 1948;238:787.
6. Pearson OH, Eliel LP. Use of primary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. JAMA 1950;144:1349.
7. Trigg ME, Gaynon P, Uckun FM. Acute lymphoblastic leukemia in children. In: Holland JF, Fry E III, Bast RC Jr., Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer medicine. 4th edition. 1996:2945-60.
8. Pui CH. Childhood leukemias. N Engl J Med 1995;332:1618.
9. Nesbit ME, Sather HN, Robison LL, Ortega J, Littman PS, D'Angio GJ, et al. Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: comparison of 1800 rad and 2400 rad. A report for Children's Cancer Study Group. Lancet 1981;1: 461.
10. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-95.
11. Bleyer WA, Coccia PF, Sather HN, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1983;1:317-25.
12. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330-6.
13. Stehbens JA, Kaleita TA, Noll RB, et al. CNS prophylaxis of childhood leukemia: what are the long-term neurological, neuropsychological, and behavioral effects? Neuropsychol Rev 1991;2:147-77.
14. Jankovic M, Brouwers P, Valsecchi MG, et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 1994;344:224-7.
15. Smith M, Arthur D, Camitta B, Carroll AJ, Grist W, Gaynon P, et al. A uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia (ALL). J Clin Oncol 1996;14(1):18-24.
16. Pitter J, Creutzig V, Reiter A, Richin H, Schellong G. Childhood leukemia: cooperative Berlin-Frankfurt-Meunster trials in the Federal Republic of Germany. J Cancer Res Clin Oncol 1990;116:100-18.
17. Tubergen D, Gilchrist G, O'Brien A, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 1990;11:527-37.
18. Nachman J, Sather HN, Gaynon PS, et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997;15:2222-30.
19. Chessels JM, Swansbury GJ, Reeves B, et al. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997;99:93-100.
20. Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990;76:1449-63.
21. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997;278:1059-64.
22. Kees UR, Burton PR, Lu C, et al. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 1997; 89:4161-6.
23. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group Study. Blood 1997;89:1143-52.
24. Kaspers GJ, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995;85:751-8.
25. Tse W, Zhu W, Chen HS, Cohen A. A novel gene AF1q, fused to MLL in t(1;11)(q21;q23) is specifically expressed in leukemia and immature hematopoietic cells. Blood 1995;83: 650-6.
26. Prasad R, Leshkowitz D, Gy Y, Alder H, Nakamura T, Saito H, et al. Leucine-zipper dimerization motif encoded by AF17 gene fused to ALL-1 (MLL) in acute leukemia. Proc Natl Acad Sci USA 1994;91:8107-11.
27. So CW, Caldas C, Liu MM, Chen SJ, Huang QH, Gu LJ, et al. EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia. Proc Natl Acad Sci USA 1997;94:2563-8.
28. Kawakami Y, et al. Bruton's tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity. Proc Natl Acad Sci USA 1997;94:3938-42.
29. Uckun FM. Severe combined immunodeficient mouse models of human leukemia [review]. Blood 1996;88(4):1135-46.
30. Uckun FM, Sather H, Reaman G, Shuster J, Land V, Trigg M, et al. Leukemic cell growth in SCID mice as a predictor of relapse in high risk B-lineage acute lymphoblastic leukemia. Blood 1995;85:873-8.
31. Uckun FM, Sather HN, Waurzyniak BJ, Sensel MG, Chelstrom L, Ek O, et al. Prognostic significance of B-lineage leukemic cell growth in SCID mice: a Children's Cancer Group Study. Leuk Lymphoma. In press.